Soluble cytokine receptors in biological therapy

Expert Opinion on Biological Therapy

Volumn 2, Issue 6, 2002, Pages 585-605

  Fernandez Botran, Rafael ^a   Crespo, Fabian A ^a   Sun, Xichun ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Asthma; Biotherapy; Cytokines; IL; Inflammation; Receptors; Soluble cytokine receptors; TNF

Indexed keywords

CYTOKINE RECEPTOR; ETANERCEPT; FC RECEPTOR; GAMMA INTERFERON RECEPTOR; GLYCOPROTEIN GP 130; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; GROWTH FACTOR; HYBRID PROTEIN; IMMUNOGLOBULIN G1; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 18; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 5 RECEPTOR; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; LENERCEPT; LIGAND; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TENETUSE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ALLERGY; ANIMAL EXPERIMENT; ANIMAL MODEL; ASTHMA; BINDING AFFINITY; BIOLOGICAL THERAPY; CHEMICAL MODIFICATION; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; HUMAN; IMMUNOGENICITY; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT;

ASTHMA; BIOLOGICAL THERAPY; CYTOKINES; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOTHERAPY; INFLAMMATION; PROTEIN BINDING; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 0036678905     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.6.585     Document Type: Review

References (177)

1. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro
2. Soluble cytokine receptors: Novel immunotherapeutic agents
3. Soluble receptors in human disease
4. The potential biological and clinical significance of the soluble tumour necrosis factor receptors
5. Clinical and pharmacological experience with etanercept
6. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation and death
7. Processing of tumour necrosis factor-α precursor by metalloproteinases
8. The murine interleukin-4 receptor: Molecular cloning and characterization of secreted and membrane bound forms
9. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism
10. Cloning of the human and murine interleukin-7 receptors: Demonstration of a soluble form and homology to a new receptor superfamily
11. Contrasting interleukin-2 binding properties of the α (p55) and β (p70) protein subunits of the human high affinity interleukin-2 receptor
12. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL-5-specific α chain and a β chain shared with the receptor for GM-CSF
13. Cytokine receptors and signal transduction
14. Signalling through the hematopoietic cytokine receptors
15. Gp130 and the interleukin-6 family of cytokines
16. The soluble IL-6 receptor: Mechanisms of production and implications in disease
17. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo
18. Multifunctional regulation of the biological effects of TNF-α by the soluble Type I and Type II TNF receptors
19. Evidence that natural murine soluble interleukin-4 receptors may act as transport proteins
20. Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
21. Stabilization of the bioactivity of tumour necrosis factor by its soluble receptors
22. Soluble interleukin-4 receptors as carrier proteins: Their effects on the pharmacokinetics of murine IL-4 in vivo
23. Anticytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes
24. Characterization and pharmacokinetic parameters of recombinant soluble interleukin-4 receptor
25. Pharmacokinetic parameters and biodistribution of soluble cytokine receptors
26. Construction, purification and characterization of new interferon γ (IFN-γ) inhibitor proteins
27. Animal pharmacokinetics of the tumour necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans
28. Cytokines and their receptors
29. Interleukin-1, tumour necrosis factor and their specific inhibitors
30. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF)
31. Cytokines and and cytokines in the pathogenesis of sepsis
32. Soluble cytokine receptors: Basic immunology and clinical applications
33. Cytokines and their receptors as therapeutic targets in asthma
34. T cell subsets (Th1 versus Th2)
35. The soluble interleukin-2 receptor: Biology, function and clinical application
36. Inhibition of acute myelogenous leukaemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors
37. The role of tumour necrosis factor in health and disease
38. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation
39. Protective effect of 55 kD but not 75 kD soluble TNF receptor-IgG fusion proteins in an animal model of Gram-negative sepsis
40. Evaluation of interleukin-1 receptor antagonist (IL-IRA) and tumour necrosis factor binding protein (TNF-BP) in a rodent abcess model of host resistance
41. Antiarthritic activity of soluble tumour necrosis factor receptor type I forms in adjuvant arthritis: Correlation of plasma levels with efficacy
42. Biological insights from clinical trials with anti-TNF therapy
43. Recombinant soluble tumour necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality
44. Involvement of 26-kDa cell-associated TNF-α in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor
45. Visceral ischaemia-reperfusion injury promotes tumour necrosis factor (TNF) and interleukin-1 (IL-1) dependent organ injury in the mouse
46. A mouse model of lung injury induced by microbial products: Implication of tumour necrosis factor
47. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration
48. Treatment of septic shock with the tumour necrosis factor receptor: Fc fusion protein
49. Why immunomodulatory therapies have not worked in sepsis
50. P55 tumour necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial
51. Impact of immunomodualting therapy on morbidity in patients with severe sepsis
52. Antitumour necrosis factor therapy in sepsis: Update on clinical trials and lessons learned
53. Evolution of collagen arthritis in mice is arrested by treatment with antitumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
54. Influence of a recombinant human soluble tumour necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice
55. Etanercept therapy in rheumatoid arthritis
56. Etanercept in rheumatoid arthritis
57. Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p75)-Fc fusion protein
58. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
59. Safety and efficacy of tumour necrosis factor receptor p75 fusion protein (TNF-R:Fc, Enbrel) in polyarticular course juvenile rheumatoid arthritis (RA)
60. Etanercept-induced subacute cutaneous erythematosus
61. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumour necrosis factor alpha receptor IgG1-Fc fusion complex therapy
62. How do the biologics fit into the current DMARD arm amentarium?
63. Transient hyperthyroidism in a patient with rheumatoid treated by etanercept
64. Thirty month treatment with a TNF-α receptor-fusion protein (TNF-R55-IgG1, RO45-2081) in patients with severe refractory RA
65. Immune response to a recombinant human TNF-R55-IgG1 fusion protein: Auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities
66. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease
67. Etanercept in the treatment of active refractory Crohn's disease: A single-center pilot trial
68. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
69. Safety and efficacy of a soluble p75 tumour necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure
70. The role of cytokines in the neuropathology of stroke and neurotrauma
71. Results of targeted antitumour necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure
72. Tumour necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure
73. Clinical trials update: CAPPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001
74. Inhibition of tumour necrosis factor-alpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat
75. Neuroprotective effects of TNF binding protein in focal cerebral ischaemia
76. Inhibition of tumour necrosis factor and amelioration of brain infarction in mice
77. Tumour necrosis factor alpha: A mediator of focal ischemic brain injury
78. TNF-α receptor fusion protein prevents experimental autoimmune encephalomyelitis and demyelination in Lewis rats: An overview
79. TNF neutralization in MS. Results of a randomized, placebo-controlled multicenter study
80. Prevention of autoimmune mellitus in NOD mice by transgenic expression of soluble tumour necrosis factor receptor p55
81. Inhibition of submandibular and lacrimal gland infiltration in nonobese diabetic mice by transgenic expression of soluble TNF-receptor p55
82. NO increases insulin sensitivity after a single intravenous administration of a recombinant human tumour necrosis factor receptor: Fc fusion protein in obese insulin resistant patients
83. Elevated plasma levels of soluble tumour necrosis factor receptor (sTNF-Rp60) reflected severity of acute pancreatitis
84. Timing of tumour necrosis factor antagonism is critical in determining outcome in murine lethal acute pancreatitis
85. Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice
86. The use of synthetic analogues of Arg-Gly-Asp (RGD) and soluble receptor of tumour necrosis factor to prevent acute and chronic experimental liver injury
87. TNF and IL-6 mediate MIP-1α expression in bleomycin induced lung injury
88. Soluble tumour necrosis factor receptor prevents postpump syndrome
89. The locus of tumour necrosis factor-alpha action in lung inflammation
90. Tumour necrosis factor mediates lung antibacterial host defense in m urine Klebsiella pneumonia
91. Inhibition of tumour necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver
92. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats
93. Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor 1
94. Transgenic mice expressing soluble tumour necrosis factor-receptor are protected against bone loss caused by oestrogen deficiency
95. Attenuation of skeletal muscle ischaemia/reperfusion injury by inhibition of tumour necrosis factor
96. Effect of inhibitor of tumour necrosis factor alpha on experimental otitis media with effusion
97. Etanercept therapy for immune-mediated cochleovestibular disorders: Preliminary results in a pilot study
98. Challenging cytokine redundancy: Inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin deficient but not tumour necrosis factor deficient mice
99. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic lipsome complex into the central nervous system
100. Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor
101. Etanercept reduced hyperalgesia in experimental painful neuropathy
102. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: A clinical and magnetic imaging study
103. New treatment options in spondyloarthropathies: Increasing evidence for significant efficacy of antitumour necrosis factor therapy
104. Rapid remission of treatment resistant ankylosing spondylitis with etanercept: A drug for refractory ankylosing spondylitis?
105. TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival
106. Differential expression of macrophage inflammatory protein and monocyte chemoattractant protein-1 in experimental glomerulonephritis
107. Antagonization of TNF attenuates systemic hemodynamic manifestations of envenomation in a rat model of Vipera aspis snakebite
108. Hereditary periodic fever syndromes
109. Inhibition of tumour necrosis prevents warming-induced sleep responses in rabbits
110. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
111. Transcending conventional therapies: The role of biologic and other novel therapies
112. Integrating antitumour necrosis factor therapy in inflammatory bowel disease: Current and future perspectives
113. Treatment options for rheumatoid arthritis: Celecoxib, leflunomide, etanercept and infliximab
114. Binding and functional comparisons of two types of tumour necrosis factor antagonists
115. Infliximab: A review of its use in the management of rheumatoid arthritis
116. A cost-cost study comparing eranercept with infliximab in rheumatoid arthritis
117. Interleukin-4: A prototypic immunoregulatory lymphokine
118. Human interleukin-4 receptor confers biological responsiveness and defines a novel receptor superfamily
119. Sharing of the interleukin-2 (IL-2) receptor γ chain between receptors for IL-2 and IL-4
120. Cloning and characterization of a binding subunit of the interleukin-13 receptor that is also a component of the interleukin-4 receptor
121. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor
122. Recombinant soluble interleukin-4 (IL-4) receptor acts as an antagonist of IL-4 in murine cutaneous leishmaniasis
123. Cure of murine candidiasis by recombinant soluble interleukin-4 receptor
124. A recombinant extracellular domain of the human interleukin-4 receptor inhibits the biological effects of interleukin-4 on T and B lymphocytes
125. Soluble interleukin-4 receptors inhibit IL-4 driven proliferation and IgE production by PBMNC of atopic children and counteract human TH2-like cells from the site of allergy
126. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma
127. Cytokine-directed therapies for asthma
128. Phase I nebulization study of recombinant human IL-4 receptor (rhuIL-4R) in adult patients with mild atopic asthma
129. Phase I/II study of interleukin-4 receptor (IL-4R) in moderate asthma
130. Interleukin-4 receptor in moderate atopic asthma: A Phase I/II randomized, placebo-controlled trial
131. Effects of recombinant human soluble interleukin-4 receptor on interleukin-4/staphylococcal enterotoxin B-stimulated peripheral mononuclear cells from patients with atopic eczema
132. Therapeutic protective effects of IL-12 combined with soluble IL-4 receptor against established infections of herpes simplex virus type 1 in thermally injured mice
133. Immunoregulation by recombinant interleukin-4 receptor (IL-4R) of murine GvH and SLE-like diseases in BDF1 hybrid mice and MRL/Ipr autoimmune mice
134. Inhibiting the effects of cytokines in human diseases
135. Interleukin-1 signalling occurs exclusively via the type I receptor
136. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4
137. Specific binding of interleukin-1 (IL-1)β and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I
138. Soluble type II interleukin-1 (IL-1) receptor binds and blocks processing of IL-1β precursor and loses affinity for IL-1 receptor antagonist
139. Retention of ligand binding activity by the extracellular domain of the IL-1 receptor
140. Experimental autoimmune encephalomyelitis is exacerbated by IL-1 α and suppressed by soluble IL-1 receptor
141. Immunomodulatory activity of recombinant IL-1 receptor (IL-1-R) on models of experimental rheumatoid arthritis
142. Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor
143. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis
144. Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients
145. A Phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukaemia
146. Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor
147. Type II interleukin-1beta receptor: A candidate for gene therapy in humans arthritis
148. Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: Radiologic assessment
149. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis
150. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis
151. Anakinra (Kineret) for rheumatoid arthritis
152. Treatment of rheumatoid arthritis with recombinant interleukin-1 receptor antagonist
153. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate
154. The ciliary neurotrophic factor receptor α component induces the secretion of and is required for functional responses to cardiotropin-like cytokine
155. Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo
156. Major role of the soluble interleukin-6/interleukin-6 receptor complex in the proliferation of interleukin-6-dependent human myeloma cell lines
157. Blockade of interleukin-6 trans-signalling suppresses T cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn's disease and experimental colitis in vivo
158. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease
159. Antagonism of the IL-6 cytokine subfamily - A potential strategy for more effective therapy in rheumatoid arthritis
160. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody
161. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy
162. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys
163. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130
164. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignalling responses
165. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation
166. In vitro and in vivo activities of the gp130-designer cytokine Hyper-IL-6
167. Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury
168. Sympathetic neurons can produce and respond to interleukin 6
169. A major binding protein for leukaemia inhibitory factor in normal mouse serum: Identification as a soluble form of the cellular receptor
170. Identification and characterization of two distinct truncated forms of gp130 and a soluble form of leukaemia inhibitory factor receptor α-chain in normal human urine and plasma
171. In vitro characterization of the human recombinant soluble granulocyte-macrophage colony-stimulating factor receptor
172. The human hematopoietic colony-stimulating factors
173. The IFN-gamma receptor: A paradigm for cytokine receptor signalling
174. Mouse soluble IFN-γ receptor as IFN-γ inhibitor. Distribution, antigenicity and activity after injection in mice
175. Experimental therapy of systemic lupus erythematosus: The treatment of NZB/W mice with mouse soluble interferon-γ receptor inhibits the onset of glomerulonephritis
176. Selective blockade of IL-15 by soluble IL-15 receptor alpha-chain enhances cardiac allograft survival
177. Targeting interleukin-18 with interleukin-18 binding protein